ResMed Inc.
At today's price, ResMed Inc. (RMD) is priced for +5.5% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• ResMed is the leader in sleep-apnea care, selling flow-generator devices and, more importantly, the masks and accessories patients replace on a recurring basis, with a growing Residential Care Software arm layered on top. • The recurring-revenue model is the moat: masks and accessories grew 12 percent globally last quarter and the consumables base resets demand every year, which is why the price implies only modest operating growth of about 4 percent a year rather than a heroic assumption. • W
Is RMD overvalued? See what's priced in →
904 institutional managers reported holding RMD in 13F filings for the quarter ended 2026-03-31. Together they hold about 66% of the company; the top 10 hold 39%. 85 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 12.9M shares were sold short as of the 2026-06-15 count, about 9% of shares outstanding (9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
RMD's share count is about flat over the past five years ($950.07M of repurchases, offset by issuance). It pays a dividend, and has for 14 years running, raised 13 years straight; the current rate is $2.12 a share annually. Cash returned over the past three years: $855.77M in dividends and $950.07M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at RMD over the trailing three years. Absence is a fact about the company, not a signal. 16 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
RMD's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-12 | -19.3% | -21.9% |
| 2023-10-28 | -4.2% | +27.8% |
| 2024-01-26 | +6.5% | +4.1% |
| 2024-04-27 | +18.6% | -12.2% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
RMD's latest 8-K filings: 2026-07-07 (items 2.02, 7.01, 9.01); 2026-04-30 (items 5.02, 9.01); 2026-04-30 (items 2.02, 8.01, 9.01); 2026-01-29 (items 2.02, 8.01, 9.01); 2025-11-20 (items 5.02, 5.07, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.